<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11931618</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-2623</ISSN><JournalIssue CitedMedium="Print"><Volume>45</Volume><Issue>8</Issue><PubDate><Year>2002</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors.</ArticleTitle><Pagination><StartPage>1644</StartPage><EndPage>1655</EndPage><MedlinePgn>1644-55</MedlinePgn></Pagination><Abstract><AbstractText>When skeletons of Win compounds were used as templates, computer-assisted drug design led to the identification of a novel series of imidazolidinone derivatives with significant antiviral activity against enterovirus 71 (EV 71), the infection of which had resulted in about 80 fatalities during the 1998 epidemic outbreak in Taiwan. In addition to inhibiting all the genotypes (A, B, and C) of EV 71 in the submicromolar to low micromolar range, compounds 1 and 8 were extensively evaluated against a variety of viruses, showing potent activity against coxsackievirus A9 (IC(50) = 0.47-0.55 microM) and coxsackievirus A24 (IC(50) = 0.47-0.55 microM) as well as moderate activity against enterovirus 68 (IC(50) = 2.13 microM) and echovirus 9 (IC(50) = 2.6 microM). Our SAR studies revealed that imidazolidinone analogues with an aryl substituent at the para position of the phenoxyl ring, such as compounds 20, 21, 27, 57, 58, and 61, in general exhibited the highest activity against EV 71. Among them, compound 20 and its corresponding hydrochloride salt 57, in terms of potency and selectivity index, appear to be the most promising candidates in this series for further development of anti-EV-71 agents. Preliminary results of the study on the mode of action by a time-course experiment suggest that test compounds 1 and 8 can effectively inhibit the virus replication at the early stages, referring to virus attachment or uncoating. This indicates that the surface protein may be the target for this type of compounds.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shia</LastName><ForeName>Kak-Shan</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei 11529, Taiwan, R.O.C. srshih@mail.cgu.edu.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wen-Tai</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chung-Ming</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Ming-Chu</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Jyh-Haur</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Leong</LastName><ForeName>Max K</ForeName><Initials>MK</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Sung-Nien</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chung-Chi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yen-Chun</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shu-Jen</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Kuan-Chang</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Huan-Yi</ForeName><Initials>HY</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Tai</LastName><ForeName>Chia-Liang</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C453478">1-(5-(biphenyl-4-yloxy)pentyl)-3-pyridin-4-ylimidazolidin-2-one</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010069">Oxadiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010080">Oxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9H4570Q89D</RegistryNumber><NameOfSubstance UI="C115201">pleconaril</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010069" MajorTopicYN="N">Oxadiazoles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010080" MajorTopicYN="N">Oxazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="Y">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>7</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>4</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId><ArticleId IdType="doi">10.1021/jm010536a</ArticleId><ArticleId IdType="pii">jm010536a</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>